Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Sangamo Therapeutics's R&D Expenses for the twelve months ending Mar 31, 2026 was $113.23M, up 11.4% year over year. For fiscal 2025 it was $112.67M, up 1.0% from the year before. Over ten years it grew 5.3% a year on average. The highest annual figure on record is $249.90M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.67M | +1.0% |
| FY2024 | Dec 31, 2024 | $111.52M | -52.4% |
| FY2023 | Dec 31, 2023 | $234.06M | -6.3% |
| FY2022 | Dec 31, 2022 | $249.90M | +8.3% |
| FY2021 | Dec 31, 2021 | $230.82M | +27.8% |
| FY2020 | Dec 31, 2020 | $180.65M | +23.8% |
| FY2019 | Dec 31, 2019 | $145.92M | +27.0% |
| FY2018 | Dec 31, 2018 | $114.87M | +74.8% |
| FY2017 | Dec 31, 2017 | $65.73M | +0.2% |
| FY2016 | Dec 31, 2016 | $65.62M | -2.4% |
| FY2015 | Dec 31, 2015 | $67.20M | +17.9% |
| FY2014 | Dec 31, 2014 | $56.97M | +53.8% |
| FY2013 | Dec 31, 2013 | $37.04M | +16.8% |
| FY2012 | Dec 31, 2012 | $31.71M | -1.2% |
| FY2011 | Dec 31, 2011 | $32.10M | -3.2% |
| FY2010 | Dec 31, 2010 | $33.15M | +14.4% |
| FY2009 | Dec 31, 2009 | $28.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $26.57M | +2.2% |
| Q4 FY2025 | Dec 31, 2025 | $31.44M | +32.8% |
| Q3 FY2025 | Sep 30, 2025 | $28.14M | +1.5% |
| Q2 FY2025 | Jun 30, 2025 | $27.08M | +11.8% |
| Q1 FY2025 | Mar 31, 2025 | $26.01M | -27.5% |
| Q4 FY2024 | Dec 31, 2024 | $23.68M | -53.3% |
| Q3 FY2024 | Sep 30, 2024 | $27.73M | -51.4% |
| Q2 FY2024 | Jun 30, 2024 | $24.22M | -61.6% |
| Q1 FY2024 | Mar 31, 2024 | $35.89M | -43.2% |
| Q4 FY2023 | Dec 31, 2023 | $50.71M | -23.4% |
| Q3 FY2023 | Sep 30, 2023 | $57.09M | -12.3% |
| Q2 FY2023 | Jun 30, 2023 | $63.05M | +5.0% |
| Q1 FY2023 | Mar 31, 2023 | $63.22M | +7.9% |
| Q4 FY2022 | Dec 31, 2022 | $66.18M | +27.8% |
| Q3 FY2022 | Sep 30, 2022 | $65.12M | +4.2% |
| Q2 FY2022 | Jun 30, 2022 | $60.02M | -0.1% |
| Q1 FY2022 | Mar 31, 2022 | $58.58M | +3.8% |
| Q4 FY2021 | Dec 31, 2021 | $51.80M | -1.1% |
| Q3 FY2021 | Sep 30, 2021 | $62.50M | +38.0% |
| Q2 FY2021 | Jun 30, 2021 | $60.09M | +44.7% |
| Q1 FY2021 | Mar 31, 2021 | $56.43M | +36.1% |
| Q4 FY2020 | Dec 31, 2020 | $52.36M | +36.6% |
| Q3 FY2020 | Sep 30, 2020 | $45.29M | +24.8% |
| Q2 FY2020 | Jun 30, 2020 | $41.52M | +13.9% |
| Q1 FY2020 | Mar 31, 2020 | $41.48M | +19.0% |
| Q4 FY2019 | Dec 31, 2019 | $38.33M | +15.3% |
| Q3 FY2019 | Sep 30, 2019 | $36.29M | +26.0% |
| Q2 FY2019 | Jun 30, 2019 | $36.46M | +24.6% |
| Q1 FY2019 | Mar 31, 2019 | $34.85M | +48.0% |
| Q4 FY2018 | Dec 31, 2018 | $33.25M | +71.6% |
| Q3 FY2018 | Sep 30, 2018 | $28.81M | +56.4% |
| Q2 FY2018 | Jun 30, 2018 | $29.26M | +95.2% |
| Q1 FY2018 | Mar 31, 2018 | $23.55M | +81.9% |
| Q4 FY2017 | Dec 31, 2017 | $19.38M | +39.5% |
| Q3 FY2017 | Sep 30, 2017 | $18.43M | +8.3% |
| Q2 FY2017 | Jun 30, 2017 | $14.98M | -23.0% |
| Q1 FY2017 | Mar 31, 2017 | $12.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $13.89M | – |
| Q3 FY2016 | Sep 30, 2016 | $17.01M | – |
| Q2 FY2016 | Jun 30, 2016 | $19.45M | – |
See a number that looks wrong?